- Home
- LNG vs REGN Comparison
LNG vs REGN Comparison
Compare LNG & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LNG | REGN |
|---|---|---|
| Founded | 1983 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.5B | 68.8B |
| IPO Year | 1996 | 1995 |
Fundamental Metrics
Financial Performance| Metric | LNG | REGN |
|---|---|---|
| Price | $279.99 | $828.96 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 25 |
| Target Price | $294.87 | ★ $830.16 |
| AVG Volume (30 Days) | ★ 1.5M | 724.3K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | ★ 0.82% | 0.55% |
| EPS Growth | ★ 69.93 | 8.19 |
| EPS | N/A | ★ 18.95 |
| Revenue | ★ $19,976,000,000.00 | $5,872,227,000.00 |
| Revenue This Year | $16.48 | $12.45 |
| Revenue Next Year | $5.89 | $10.13 |
| P/E Ratio | ★ N/A | $44.01 |
| Revenue Growth | ★ 27.21 | 20.82 |
| 52 Week Low | $186.20 | $541.00 |
| 52 Week High | $300.94 | $847.00 |
Technical Indicators
Market Signals| Indicator | LNG | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 63.84 | 73.76 |
| Support Level | $250.03 | $732.04 |
| Resistance Level | $300.22 | N/A |
| Average True Range (ATR) | 6.17 | 19.12 |
| MACD | 1.24 | 1.01 |
| Stochastic Oscillator | 96.71 | 78.77 |
Price Performance
Historical ComparisonAbout LNG Cheniere Energy Inc.
Cheniere Energy is a liquefied natural gas producer with two facilities in Corpus Christi, Texas, and Sabine Pass, Louisiana. It generates most of its revenue through long-term contracts with customers on a fixed- and variable-fee payout structure. It also generates revenue by selling uncontracted LNG to customers on a short or one-time basis. A subsidiary, Cheniere Energy Partners, owns the Sabine Pass facility and trades as a master limited partnership.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.